Free tool
FAERS Monitor: Pluvicto
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215833 or its brand name (Pluvicto, Lutetium Lu-177 Vipivotide Tetraxetan). Reports on generic versions are filed under their own applications.
Reports
13,841
Serious
3,364
24% of reports
Hospitalization
725
Death reported
1,680
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- general physical health deterioration6,684
- ill-defined disorder3,641
- death1,321
- disease progression360
- malignant neoplasm progression343
- prostatic specific antigen increased287
- laboratory test abnormal266
- fatigue238
- anaemia204
- platelet count decreased168
- hormone-refractory prostate cancer167
- illness165
- haemoglobin decreased159
- thrombocytopenia147
- covid-19146
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2022 | 622 |
| 2023 | 3,535 |
| 2024 | 3,984 |
| 2025 | 3,457 |
| 2026 | 2,242 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,318 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hormone-refractory prostate cancerSignal | 167 | 248.6 | 211.3 | 35,189 |
| ill-defined disorderSignal | 3,641 | 96.8 | 94.0 | 325,422 |
| general physical health deteriorationSignal | 6,684 | 93.1 | 91.4 | 576,936 |
| prostatic specific antigen increasedSignal | 287 | 32.3 | 28.8 | 8,501 |
| laboratory test abnormalSignal | 266 | 13.8 | 12.3 | 3,125 |
| malignant neoplasm progressionSignal | 343 | 5.1 | 4.6 | 1,129 |
| disease progressionSignal | 360 | 4.6 | 4.2 | 1,025 |
| illnessSignal | 165 | 2.4 | 2.1 | 139 |
| platelet count decreasedSignal | 168 | 2.4 | 2.1 | 136 |
| haemoglobin decreasedSignal | 159 | 2.4 | 2.0 | 123 |
| deathSignal | 1,321 | 2.3 | 2.2 | 1,045 |
| thrombocytopenia | 147 | 2.0 | 1.7 | 73 |
| anaemia | 204 | 1.6 | 1.4 | 49 |
| covid-19 | 146 | 1.3 | 1.1 | 8 |
| fatigue | 238 | 0.5 | 0.4 | 152 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.